Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma

Ying Zeng, Agnieszka A. Rucki, Xu Che, Lei Zheng

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Pancreatic adenocarcinoma is still widely considered as a deadly disease even though there are substantial therapeutic developments in the past decade. Using combinational chemotherapy regimens, represented by gemcitabine plus nab-paclitaxel and FOLFIRINOX, was able to improve overall survival in patients with advanced disease to a limited extent. It has been a challenge to develop targeted therapies that are focused on the neoplasm cells of pancreatic adenocarcinoma. Recently, targeting the stroma and immune compartments of pancreatic adenocarcinoma has shown promising results. The paradigm of biologics drug development therefore has been shifted by extending to these exciting areas. Although some of the preclinical and clinical researches in targeting the tumor microenvironment of pancreatic adenocarcinoma have shown promising results, others have resulted in controversial findings. Both comprehensive and indepth researches on the basic science of the tumor microenvironment of pancreatic adenocarcinoma are thus warranted for the development of effective biologics that target the tumor microenvironment.

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalJournal of Gastrointestinal Oncology
Issue number3
StatePublished - Jun 1 2017


  • Chemotherapy
  • Immunotherapy
  • Pancreatic adenocarcinoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma'. Together they form a unique fingerprint.

Cite this